Harmony Biosciences Holdings, Inc. (HRMY)
38.51
+0.36
(+0.94%)
USD |
NASDAQ |
Aug 24, 16:00
38.51
0.00 (0.00%)
After-Hours: 20:00
Harmony Biosciences Holdings Enterprise Value : 1.770B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 1.770B |
| August 20, 2026 | 1.766B |
| August 19, 2026 | 1.874B |
| August 18, 2026 | 1.810B |
| August 17, 2026 | 1.770B |
| August 14, 2026 | 1.769B |
| August 13, 2026 | 1.791B |
| August 12, 2026 | 1.865B |
| August 11, 2026 | 1.850B |
| August 10, 2026 | 1.820B |
| August 07, 2026 | 1.786B |
| August 06, 2026 | 1.805B |
| August 05, 2026 | 1.776B |
| August 04, 2026 | 1.807B |
| August 03, 2026 | 1.622B |
| July 31, 2026 | 1.601B |
| July 30, 2026 | 1.637B |
| July 29, 2026 | 1.637B |
| July 28, 2026 | 1.632B |
| July 27, 2026 | 1.646B |
| July 24, 2026 | 1.606B |
| July 23, 2026 | 1.634B |
| July 22, 2026 | 1.579B |
| July 21, 2026 | 1.694B |
| July 20, 2026 | 1.500B |
| Date | Value |
|---|---|
| July 17, 2026 | 1.516B |
| July 16, 2026 | 1.502B |
| July 15, 2026 | 1.582B |
| July 14, 2026 | 1.576B |
| July 13, 2026 | 1.619B |
| July 10, 2026 | 1.694B |
| July 09, 2026 | 1.774B |
| July 08, 2026 | 1.766B |
| July 07, 2026 | 1.777B |
| July 06, 2026 | 1.704B |
| July 02, 2026 | 1.719B |
| July 01, 2026 | 1.646B |
| June 30, 2026 | 1.669B |
| June 29, 2026 | 1.611B |
| June 26, 2026 | 1.618B |
| June 25, 2026 | 1.541B |
| June 24, 2026 | 1.559B |
| June 23, 2026 | 1.542B |
| June 22, 2026 | 1.500B |
| June 18, 2026 | 1.491B |
| June 17, 2026 | 1.520B |
| June 16, 2026 | 1.523B |
| June 15, 2026 | 1.544B |
| June 12, 2026 | 1.560B |
| June 11, 2026 | 1.603B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Liquidia Corp. | 6.013B |
| Repligen Corp. | 10.10B |
| Johnson & Johnson | 679.08B |
| ACADIA Pharmaceuticals, Inc. | 4.195B |
| ANI Pharmaceuticals, Inc. | 1.966B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 75.43M |
| Revenue (Quarterly) | 261.28M |
| Total Expenses (Quarterly) | 185.85M |
| EPS Diluted (Quarterly) | 1.284 |
| Gross Profit Margin (Quarterly) | 73.53% |
| Profit Margin (Quarterly) | 28.87% |
| Earnings Yield | 8.01% |
| Operating Earnings Yield | 10.20% |
| Normalized Earnings Yield | 8.013 |